28 March 2019

Geneva Supports Ebola Research Advancement

The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), in collaboration with Geneva and Gilead Sciences, Inc., has announced that the U.S. Food and Drug Administration (FDA) has provided formal regulatory agreement for use of an animal model to support development of a drug candidate, remdesivir, for treating deadly Ebola virus (EBOV) infections.

USAMRIID and Gilead Sciences, Inc. worked in close partnership to develop the study plan for conducting the IM/EBOV NHS in rhesus monkeys, analyze the study outcome and submit data to the FDA. A team of over 100 USAMRIID and Geneva personnel, representing the divisions of Molecular and Translational Sciences, Virology, Telemetry, Pathology, Veterinary Medicine, Advanced Research Studies, and Quality Assurance participated in the study, which was conducted in a Biosafety Level 4 (BSL-4) laboratory under maximum containment conditions.

Read the full press release to learn more about this new advancement in Ebola research. Click here to learn about Geneva’s work in infectious diseases.